Individuals who received valsartan that was subject to a global recall due to contamination with the cancer-linked compound N-nitrosodimethylamine didn't have increased overall cancer risk in the short term and had slightly, but not statistically significant, higher odds of uterine and colorectal cancers, according to a Danish study in The BMJ. However, more studies are needed to evaluate the possible likelihood of specific cancers and long-term adverse effects associated with contaminated valsartan, researchers said.
Recalled valsartan not tied to higher short-term cancer risk
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.